Pivotal	B-study_type
Trial	I-study_type
of	O
Enfortumab	B-arm_description
Vedotin	I-arm_description
in	O
Urothelial	O
Carcinoma	O
After	O
Platinum	O
and	O
Anti	O
-	O
Programmed	O
Death	O
1	O
/	O
Programmed	O
Death	O
Ligand	O
1	O
Therapy	O
Pivotal	B-study_type
Trial	I-study_type
of	O
Enfortumab	O
Vedotin	O
in	O
Urothelial	O
Carcinoma	O
After	O
Platinum	O
and	O
Anti	O
-	O
Programmed	O
Death	O
1	O
/	O
Programmed	O
Death	O
Ligand	O
1	O
Therapy	O
MDJonathanERosenberg	B-authors

Inst	O
)	O
,	O
Celldex	O
(	O
Inst	O
)	O
,	O
Inovio	O
Pharmaceuticals	O
(	O
Inst	O
)	O
,	O
Celgene	O
(	O
Inst	O
)	O
,	O
Zenith	O
Epigenetics	O
(	O
Inst	O
)	O
,	O
Merck	O
(	O
Inst	O
)	O
,	O
AstraZeneca	O
(	O
Inst	O
)	O
,	O
Esanik	O
(	O
Inst	O
)	O
,	O
Oncolys	O
BioPharma	O
(	O
Inst	O
)	O
,	O
Curemeta	O
(	O
Inst	O
)	O
,	O
Bristol	O
-	O
Myers	O
Squibb	O
(	O
Inst	O
)	O
,	O
eFFECTOR	O
Therapeutics	O
(	O
Inst	O
)	O
,	O
Fortis	O
(	O
Inst	O
)	O
,	O
Astellas	O
Pharma	O
(	O
Inst	O
)	O
,	O
Medivation	O
(	O
Inst	O
)	O
,	O
Ignyta	O
(	O
Inst	O
)	O
,	O
Synta	O
(	O
Inst	O
)	O
,	O
Caris	O
Life	O
Sciences	O
(	O
Inst	O
)	O
,	O
Boehringer	O
Ingelheim	O
(	O
Inst	O
)	O
,	O
GlaxoSmithKline	O
(	O
Inst	O
)	O
,	O
Merck	O
Sharp	O
&	O
Dohme	O
(	O
Inst	O
)	O
,	O
Plexxikon	O
(	O
Inst	O
)	O
,	O
Corcept	O
Therapeutics	O
(	O
Inst	O

Pharmacyclics	O
Research	O
Funding	O
:	O
Agensys	O
(	O
Inst	O
)	O
,	O
Astellas	O
Pharma	O
(	O
Inst	O
)	O
,	O
Dendreon	O
(	O
Inst	O
)	O
,	O
Genentech	O
(	O
Inst	O
)	O
,	O
Bayer	O
(	O
Inst	O
)	O
,	O
Merck	O
(	O
Inst	O
)	O
Daiichi	O
Sankyo	O

Bristol	O
-	O
Myers	O
Squibb	O
,	O
AstraZeneca	O
,	O
MedImmune	O
,	O
Pieris	O
Pharmaceuticals	O
,	O
Inovio	O
Pharmaceuticals	O
,	O
Genentech	O
,	O
Health	O
Advances	O
,	O
Merck	O
,	O
Ferring	O
,	O
Principia	O
Biopharma	O
,	O
Champions	O
Oncology	O
,	O
Taris	O
BioMedical	O
,	O
Seattle	O
Genetics	O
,	O
Astellas	O
Pharma	O
,	O
Incyte	O
,	O
TransMed	O
,	O
Rexahn	O
Pharmaceuticals	O
,	O
CicloMed	O
,	O
Janssen	O
Pharmaceuticals	O
Research	O
Funding	O
:	O
Genentech	O
(	O
Inst	O
)	O
,	O
Merck	O
(	O
Inst	O
)	O
,	O
Bristol	O
-	O
Myers	O
Squibb	O
(	O
Inst	O
)	O
,	O
AstraZeneca	O
(	O
Inst	O
)	O
,	O
MedImmune	O
(	O
Inst	O
)	O
,	O
Principia	O
Biopharma	O
(	O
Inst	O
)	O
,	O
Acerta	O
Pharma	O
(	O
Inst	O
)	O
,	O
Incyte	O
(	O
Inst	O
)	O
,	O
Seattle	O
Genetics	O
(	O
Inst	O
)	O
,	O
Astellas	O
Pharma	O
(	O
Inst	O
)	O
,	O
Astex	O
Pharmaceuticals	O
(	O
Inst	O
)	O
,	O
Pieris	O
Pharmaceuticals	O
(	O
Inst	O
)	O

Myers	O
Squibb	O
,	O
Clovis	O
Oncology	O
,	O
Incyte	O
,	O
Janssen	O
Pharmaceuticals	O
,	O
Pharmacyclics	O
,	O
Seattle	O
Genetics	O
,	O
Urogen	O
Pharma	O
Research	O
Funding	O
:	O
Progenics	O
(	O
Inst	O
)	O
,	O
Sanofi	O
(	O
Inst	O
)	O

Endocyte	O
(	O
Inst	O
)	O
,	O
Genentech	O
(	O
Inst	O
)	O
,	O
Merck	O
(	O
Inst	O
)	O
,	O
Astellas	O
Medivation	O
(	O
Inst	O
)	O
,	O
Novartis	O
(	O
Inst	O
)	O
,	O
AstraZeneca	O
(	O
Inst	O
)	O
,	O
Bayer	O
(	O
Inst	O
)	O
,	O
Eli	O
Lilly	O
(	O
Inst	O
)	O
,	O
Innocrin	O
Pharma	O
(	O
Inst	O
)	O
,	O
MedImmune	O
(	O
Inst	O
)	O
,	O
Pfizer	O
(	O
Inst	O
)	O

Pivotal	B-study_type
Trial	I-study_type
of	O
Enfortumab	B-arm_description
Vedotin	I-arm_description
in	O
Urothelial	O
Carcinoma	O
After	O
Platinum	O
and	O
Anti	O
-	O
Programmed	O
Death	O
1	O
/	O
Programmed	O
Death	O
Ligand	O
1	O
Therapy	O
10.1200	O
/	O
JCO.19	O

Inst	O
)	O
,	O
Celldex	O
(	O
Inst	O
)	O
,	O
Inovio	O
Pharmaceuticals	O
(	O
Inst	O
)	O
,	O
Celgene	O
(	O
Inst	O
)	O
,	O
Zenith	O
Epigenetics	O
(	O
Inst	O
)	O
,	O
Merck	O
(	O
Inst	O
)	O
,	O
AstraZeneca	O
(	O
Inst	O
)	O
,	O
Esanik	O
(	O
Inst	O
)	O
,	O
Oncolys	O
BioPharma	O
(	O
Inst	O
)	O
,	O
Curemeta	O
(	O
Inst	O
)	O
,	O
Bristol	O
-	O
Myers	O
Squibb	O
(	O
Inst	O
)	O
,	O
eFFECTOR	O
Therapeutics	O
(	O
Inst	O
)	O
,	O
Fortis	O
(	O
Inst	O
)	O
,	O
Astellas	O
Pharma	O
(	O
Inst	O
)	O
,	O
Medivation	O
(	O
Inst	O
)	O
,	O
Ignyta	O
(	O
Inst	O
)	O
,	O
Synta	O
(	O
Inst	O
)	O
,	O
Caris	O
Life	O
Sciences	O
(	O
Inst	O
)	O
,	O
Boehringer	O
Ingelheim	O
(	O
Inst	O
)	O
,	O
GlaxoSmithKline	O
(	O
Inst	O
)	O
,	O
Merck	O
Sharp	O
&	O
Dohme	O
(	O
Inst	O
)	O
,	O
Plexxikon	O
(	O
Inst	O
)	O
,	O
Corcept	O
Therapeutics	O
(	O
Inst	O

Pharmacyclics	O
Research	O
Funding	O
:	O
Agensys	O
(	O
Inst	O
)	O
,	O
Astellas	O
Pharma	O
(	O
Inst	O
)	O
,	O
Dendreon	O
(	O
Inst	O
)	O
,	O
Genentech	O
(	O
Inst	O
)	O
,	O
Bayer	O
(	O
Inst	O
)	O
,	O
Merck	O
(	O
Inst	O
)	O
Daiichi	O
Sankyo	O

Bristol	O
-	O
Myers	O
Squibb	O
,	O
AstraZeneca	O
,	O
MedImmune	O
,	O
Pieris	O
Pharmaceuticals	O
,	O
Inovio	O
Pharmaceuticals	O
,	O
Genentech	O
,	O
Health	O
Advances	O
,	O
Merck	O
,	O
Ferring	O
,	O
Principia	O
Biopharma	O
,	O
Champions	O
Oncology	O
,	O
Taris	O
BioMedical	O
,	O
Seattle	O
Genetics	O
,	O
Astellas	O
Pharma	O
,	O
Incyte	O
,	O
TransMed	O
,	O
Rexahn	O
Pharmaceuticals	O
,	O
CicloMed	O
,	O
Janssen	O
Pharmaceuticals	O
Research	O
Funding	O
:	O
Genentech	O
(	O
Inst	O
)	O
,	O
Merck	O
(	O
Inst	O
)	O
,	O
Bristol	O
-	O
Myers	O
Squibb	O
(	O
Inst	O
)	O
,	O
AstraZeneca	O
(	O
Inst	O
)	O
,	O
MedImmune	O
(	O
Inst	O
)	O
,	O
Principia	O
Biopharma	O
(	O
Inst	O
)	O
,	O
Acerta	O
Pharma	O
(	O
Inst	O
)	O
,	O
Incyte	O
(	O
Inst	O
)	O
,	O
Seattle	O
Genetics	O
(	O
Inst	O
)	O
,	O
Astellas	O
Pharma	O
(	O
Inst	O
)	O
,	O
Astex	O
Pharmaceuticals	O
(	O
Inst	O
)	O
,	O
Pieris	O
Pharmaceuticals	O
(	O
Inst	O
)	O

Myers	O
Squibb	O
,	O
Clovis	O
Oncology	O
,	O
Incyte	O
,	O
Janssen	O
Pharmaceuticals	O
,	O
Pharmacyclics	O
,	O
Seattle	O
Genetics	O
,	O
Urogen	O
Pharma	O
Research	O
Funding	O
:	O
Progenics	O
(	O
Inst	O
)	O
,	O
Sanofi	O
(	O
Inst	O
)	O

Endocyte	O
(	O
Inst	O
)	O
,	O
Genentech	O
(	O
Inst	O
)	O
,	O
Merck	O
(	O
Inst	O
)	O
,	O
Astellas	O
Medivation	O
(	O
Inst	O
)	O
,	O
Novartis	O
(	O
Inst	O
)	O
,	O
AstraZeneca	O
(	O
Inst	O
)	O
,	O
Bayer	O
(	O
Inst	O
)	O
,	O
Eli	O
Lilly	O
(	O
Inst	O
)	O
,	O
Innocrin	O
Pharma	O
(	O
Inst	O
)	O
,	O
MedImmune	O
(	O
Inst	O
)	O
,	O
Pfizer	O
(	O
Inst	O
)	O

Pivotal	B-study_type
Trial	I-study_type
of	O
Enfortumab	B-arm_description
Vedotin	I-arm_description
in	O
Urothelial	O
Carcinoma	O
After	O
Platinum	O
and	O
Anti	O
-	O
Programmed	O
Death	O
1	O
/	O
Programmed	O
Death	O
Ligand	O
1	O
Therapy	O
10.1200	O
/	O
JCO.19	O

Inst	O
)	O
,	O
Celldex	O
(	O
Inst	O
)	O
,	O
Inovio	O
Pharmaceuticals	O
(	O
Inst	O
)	O
,	O
Celgene	O
(	O
Inst	O
)	O
,	O
Zenith	O
Epigenetics	O
(	O
Inst	O
)	O
,	O
Merck	O
(	O
Inst	O
)	O
,	O
AstraZeneca	O
(	O
Inst	O
)	O
,	O
Esanik	O
(	O
Inst	O
)	O
,	O
Oncolys	O
BioPharma	O
(	O
Inst	O
)	O
,	O
Curemeta	O
(	O
Inst	O
)	O
,	O
Bristol	O
-	O
Myers	O
Squibb	O
(	O
Inst	O
)	O
,	O
eFFECTOR	O
Therapeutics	O
(	O
Inst	O
)	O
,	O
Fortis	O
(	O
Inst	O
)	O
,	O
Astellas	O
Pharma	O
(	O
Inst	O
)	O
,	O
Medivation	O
(	O
Inst	O
)	O
,	O
Ignyta	O
(	O
Inst	O
)	O
,	O
Synta	O
(	O
Inst	O
)	O
,	O
Caris	O
Life	O
Sciences	O
(	O
Inst	O
)	O
,	O
Boehringer	O
Ingelheim	O
(	O
Inst	O
)	O
,	O
GlaxoSmithKline	O
(	O
Inst	O
)	O
,	O
Merck	O
Sharp	O
&	O
Dohme	O
(	O
Inst	O
)	O
,	O
Plexxikon	O
(	O
Inst	O
)	O
,	O
Corcept	O
Therapeutics	O
(	O
Inst	O

Pharmacyclics	O
Research	O
Funding	O
:	O
Agensys	O
(	O
Inst	O
)	O
,	O
Astellas	O
Pharma	O
(	O
Inst	O
)	O
,	O
Dendreon	O
(	O
Inst	O
)	O
,	O
Genentech	O
(	O
Inst	O
)	O
,	O
Bayer	O
(	O
Inst	O
)	O
,	O
Merck	O
(	O
Inst	O
)	O
Daiichi	O
Sankyo	O

Bristol	O
-	O
Myers	O
Squibb	O
,	O
AstraZeneca	O
,	O
MedImmune	O
,	O
Pieris	O
Pharmaceuticals	O
,	O
Inovio	O
Pharmaceuticals	O
,	O
Genentech	O
,	O
Health	O
Advances	O
,	O
Merck	O
,	O
Ferring	O
,	O
Principia	O
Biopharma	O
,	O
Champions	O
Oncology	O
,	O
Taris	O
BioMedical	O
,	O
Seattle	O
Genetics	O
,	O
Astellas	O
Pharma	O
,	O
Incyte	O
,	O
TransMed	O
,	O
Rexahn	O
Pharmaceuticals	O
,	O
CicloMed	O
,	O
Janssen	O
Pharmaceuticals	O
Research	O
Funding	O
:	O
Genentech	O
(	O
Inst	O
)	O
,	O
Merck	O
(	O
Inst	O
)	O
,	O
Bristol	O
-	O
Myers	O
Squibb	O
(	O
Inst	O
)	O
,	O
AstraZeneca	O
(	O
Inst	O
)	O
,	O
MedImmune	O
(	O
Inst	O
)	O
,	O
Principia	O
Biopharma	O
(	O
Inst	O
)	O
,	O
Acerta	O
Pharma	O
(	O
Inst	O
)	O
,	O
Incyte	O
(	O
Inst	O
)	O
,	O
Seattle	O
Genetics	O
(	O
Inst	O
)	O
,	O
Astellas	O
Pharma	O
(	O
Inst	O
)	O
,	O
Astex	O
Pharmaceuticals	O
(	O
Inst	O
)	O
,	O
Pieris	O
Pharmaceuticals	O
(	O
Inst	O
)	O

Myers	O
Squibb	O
,	O
Clovis	O
Oncology	O
,	O
Incyte	O
,	O
Janssen	O
Pharmaceuticals	O
,	O
Pharmacyclics	O
,	O
Seattle	O
Genetics	O
,	O
Urogen	O
Pharma	O
Research	O
Funding	O
:	O
Progenics	O
(	O
Inst	O
)	O
,	O
Sanofi	O
(	O
Inst	O
)	O

Endocyte	O
(	O
Inst	O
)	O
,	O
Genentech	O
(	O
Inst	O
)	O
,	O
Merck	O
(	O
Inst	O
)	O
,	O
Astellas	O
Medivation	O
(	O
Inst	O
)	O
,	O
Novartis	O
(	O
Inst	O
)	O
,	O
AstraZeneca	O
(	O
Inst	O
)	O
,	O
Bayer	O
(	O
Inst	O
)	O
,	O
Eli	O
Lilly	O
(	O
Inst	O
)	O
,	O
Innocrin	O
Pharma	O
(	O
Inst	O
)	O
,	O
MedImmune	O
(	O
Inst	O
)	O
,	O
Pfizer	O
(	O
Inst	O
)	O

Pivotal	B-study_type
Trial	I-study_type
of	O
Enfortumab	B-arm_description
Vedotin	I-arm_description
in	O
Urothelial	O
Carcinoma	O
After	O
Platinum	O
and	O
Anti	O
-	O
Programmed	O
Death	O
1	O
/	O
Programmed	O
Death	O
Ligand	O
1	O
Therapy	O
MDJonathanERosenberg	B-authors
MDJonathanERosenberg	B-authors
MD	O
Jonathan	B-authors
E	I-authors
Rosenberg	I-authors
MDPeterHO'donnell	B-authors
MDPeterHO'donnell	B-authors
MD	O
Peter	B-authors
H	I-authors
O'donnell	I-authors
MDArjunVBalar	B-authors
MDArjunVBalar	B-authors
MD	O
Arjun	B-authors
V	I-authors
Balar	I-authors
MDBradleyAMcgregor	B-authors
MDBradleyAMcgregor	B-authors
MD	O
Bradley	B-authors
A	I-authors
Mcgregor	I-authors
MDElisabethIHeath	B-authors
MDElisabethIHeath	B-authors
MD	O
Elisabeth	B-authors
I	I-authors
Heath	I-authors
MDEvanYYu	B-authors
MDEvanYYu	B-authors
MD	O
Evan	B-authors
Y	I-authors
Yu	I-authors
MDMatthewDGalsky	B-authors
MDMatthewDGalsky	B-authors
MD	O
Matthew	B-authors
D	I-authors
Galsky	I-authors
MDNoahMHahn	B-authors
MDNoahMHahn	B-authors
MD	O
Noah	B-authors
M	I-authors
Hahn	I-authors
MDElainaMGartner	B-authors
MDElainaMGartner	B-authors
MD	O
Elaina	B-authors
M	I-authors
Gartner	I-authors
PA	O
-	O
C	O
,	O
MMScJuanMPinelli	B-authors
PA	O
-	O
C	O
,	O
MMScJuanMPinelli	B-authors
PA	O
-	O
C	O
,	O
MMSc	O
Juan	B-authors
M	I-authors
Pinelli	I-authors
PhDYingLiang	B-authors
PhDYingLiang	B-authors
PhD	O
Ying	B-authors
Liang	I-authors
MDAmalMelhem	B-authors
-	I-authors
Bertrandt	I-authors
MDAmalMelhem	B-authors
-	I-authors
Bertrandt	I-authors
MD	O
Amal	B-authors
Melhem	I-authors
-	I-authors
Bertrandt	I-authors
MDDanielPPetrylak	B-authors
MDDanielPPetrylak	B-authors
MD	O
Daniel	B-authors
P	I-authors
Petrylak	I-authors
Rosenberg	B-authors
Rosenberg	B-authors
Rosenberg	B-authors
Honoraria	B-authors
:	O
Merck	O
Honoraria	O
:	O
Merck	O
Honoraria	O
:	O
Merck	O
Genentech	O
Genentech	O
Genentech	O
MedImmuneAstrazeneca	O
MedImmuneAstrazeneca	O
MedImmune	O
Astrazeneca	O
JanssenPharmaceuticals	O
JanssenPharmaceuticals	O
Janssen	O
Pharmaceuticals	O
Merck	O
,	O
AstraZeneca	O
,	O
EMD	O
Serono	O
,	O
Incyte	O
,	O
Amgen	O
,	O
Tolmar	O
,	O
QEDBayer	O
Merck	O
,	O
AstraZeneca	O
,	O
EMD	O
Serono	O
,	O
Incyte	O
,	O
Amgen	O
,	O
Tolmar	O
,	O
QEDBayer	O
Merck	O
,	O
AstraZeneca	O
,	O
EMD	O
Serono	O
,	O
Incyte	O
,	O
Amgen	O
,	O
Tolmar	O
,	O
QED	O
Bayer	O
Therapeutics	O
Therapeutics	O
Therapeutics	O
NoahMHahn	B-authors
Honoraria	I-authors
NoahMHahn	B-authors
Honoraria	I-authors
Noah	B-authors
M	I-authors
Hahn	I-authors
Honoraria	I-authors
Shang	B-authors
-	I-authors
YingLiang	I-authors
Shang	B-authors
-	I-authors
YingLiang	I-authors
Shang	B-authors
-	I-authors
Ying	I-authors
Liang	I-authors
Consulting	O
or	O
Advisory	O
Role	O
:	O
Genentech	O
EMD	O
Serono	O

Merck	O
,	O
Pfizer	O
,	O
Incyte	O
,	O
Seattle	O
Genetics	O
,	O
Nektar	O
Consulting	O
or	O
Advisory	O
Role	O
:	O
Genentech	O
EMD	O
Serono	O
Cerulean	O
Pharma	O
,	O
AstraZeneca	O
,	O
MedImmune	O
,	O
Astellas	O
Pharma	O

Pharmacyclics	O
Research	O
Funding	O
:	O
Agensys	O
(	O
Inst	O
)	O
,	O
Astellas	O
Pharma	O
(	O
Inst	O
)	O
,	O
Dendreon	O
(	O
Inst	O
)	O
,	O
Genentech	O
(	O
Inst	O
)	O
,	O
Bayer	O
(	O
Inst	O
)	O
,	O
Merck	O
(	O
Inst	O
)	O

Pharmacyclics	O
Research	O
Funding	O
:	O
Agensys	O
(	O
Inst	O
)	O
,	O
Astellas	O
Pharma	O
(	O
Inst	O
)	O
,	O
Dendreon	O
(	O
Inst	O
)	O
,	O
Genentech	O
(	O
Inst	O
)	O
,	O
Bayer	O
(	O
Inst	O
)	O
,	O
Merck	O
(	O
Inst	O
)	O

Endocyte	O
(	O
Inst	O
)	O
,	O
Genentech	O
(	O
Inst	O
)	O
,	O
Merck	O
(	O
Inst	O
)	O
,	O
Astellas	O
Medivation	O
(	O
Inst	O
)	O
,	O
Novartis	O
(	O
Inst	O
)	O
,	O
AstraZeneca	O
(	O
Inst	O
)	O
,	O
Bayer	O
(	O
Inst	O
)	O
,	O
Eli	O
Lilly	O
(	O
Inst	O
)	O
,	O
Innocrin	O
Pharma	O
(	O
Inst	O
)	O
,	O
MedImmune	O
(	O
Inst	O
)	O
,	O
Pfizer	O
(	O
Inst	O
)	O

Bristol	O
-	O
Myers	O
Squibb	O
(	O
Inst	O
)	O
Myers	O
Squibb	O
,	O
Clovis	O
Oncology	O
,	O
Incyte	O
,	O
Janssen	O
Pharmaceuticals	O
,	O
Pharmacyclics	O
,	O
Seattle	O
Genetics	O
,	O
Urogen	O
Pharma	O
Research	O
Funding	O
:	O
Progenics	O
(	O
Inst	O
)	O
,	O
Sanofi	O
(	O
Inst	O
)	O

Endocyte	O
(	O
Inst	O
)	O
,	O
Genentech	O
(	O
Inst	O
)	O
,	O
Merck	O
(	O
Inst	O
)	O
,	O
Astellas	O
Medivation	O
(	O
Inst	O
)	O
,	O
Novartis	O
(	O
Inst	O
)	O
,	O
AstraZeneca	O
(	O
Inst	O
)	O
,	O
Bayer	O
(	O
Inst	O
)	O
,	O
Eli	O
Lilly	O
(	O
Inst	O
)	O
,	O
Innocrin	O
Pharma	O
(	O
Inst	O
)	O
,	O
MedImmune	O
(	O
Inst	O
)	O
,	O
Pfizer	O
(	O
Inst	O
)	O

Bristol	O
-	O
Myers	O
Squibb	O
(	O
Inst	O
)	O
Myers	O
Squibb	O
,	O
Clovis	O
Oncology	O
,	O
Incyte	O
,	O
Janssen	O
Pharmaceuticals	O
,	O
Pharmacyclics	O
,	O
Seattle	O
Genetics	O
,	O
Urogen	O
Pharma	O
Research	O
Funding	O
:	O
Progenics	O
(	O
Inst	O
)	O
,	O
Sanofi	O
(	O
Inst	O
)	O
Seattle	O
Genetics	O
(	O
Inst	O
)	O
Clovis	O
Oncology	O
(	O
Inst	O
)	O
Ada	O
Cap	O
(	O
Inst	O
)	O
Endocyte	O
(	O
Inst	O
)	O
,	O
Genentech	O
(	O
Inst	O
)	O
,	O
Merck	O
(	O
Inst	O
)	O
,	O
Astellas	O
Medivation	O
(	O
Inst	O
)	O
,	O
Novartis	O
(	O
Inst	O
)	O
,	O
AstraZeneca	O
(	O
Inst	O
)	O
,	O
Bayer	O
(	O
Inst	O
)	O
,	O
Eli	O
Lilly	O
(	O
Inst	O
)	O
,	O
Innocrin	O
Pharma	O
(	O
Inst	O
)	O
,	O
MedImmune	O
(	O
Inst	O
)	O
,	O
Pfizer	O
(	O
Inst	O
)	O
Roche	O
(	O
Inst	O
)	O

Bristol	O
-	O
Myers	O
Squibb	O
(	O
Inst	O
)	O
Roche	O
(	O
Inst	O
)	O
Bristol	O
-	O
Myers	O
Squibb	O
(	O
Inst	O
)	O
Pivotal	B-study_type
Trial	I-study_type
of	O
Enfortumab	B-arm_description
Vedotin	I-arm_description
in	O
Urothelial	O
Carcinoma	O
After	O
Platinum	O
and	O
Anti	O
-	O
Programmed	O
Death	O
1	O
/	O
Programmed	O
Death	O
Ligand	O
1	O
Therapy	O
10.1200	O
/	O
JCO.19	O
Accepted	O
on	O
May	O
24	O
,	O
2019	O
and	O
published	O

Locally	O
advanced	O
or	O
metastatic	O
urothelial	O
carcinoma	O
of	O
the	O
renal	O
pelvis	O
,	O
ureters	O
,	O
bladder	O
,	O
or	O
urethra	O
is	O
an	O
incurable	O
disease	O
with	O
poor	O
long	O
-	O
term	O
survival	O
.	O
1	O
Platinum	O
-	O
based	O
therapies	O
are	O
the	O
first	O
-	O
line	O
treatment	O
for	O
most	O
patients	O
,	O
with	O
objective	O
response	O
rates	O
of	O
41	O
%	O
to	O
50	O
%	O
and	O
median	O
progression	O
-	O
free	O
survival	O
of	O
7.6	O
months	O
.	O
[	O
2][3][4	O
]	O
In	O
the	O
postplatinum	O
setting	O
,	O
phase	O
III	O
studies	O
of	O
anti	O
-	O
programmed	O
death	O
1	O
or	O
anti	O
-	O
programmed	O
death	O
ligand	O
1	O
(	O
PD-1	O
/	O
L1	O
)	O
therapy	O
demonstrated	O
objective	O
response	O
rates	O
of	O
21	O
%	O
and	O
13	O
%	O
,	O
respectively	O
,	O
with	O
an	O
overall	O
survival	O
advantage	O
compared	O
with	O
second	O
-	O
line	O
chemotherapy	O
demonstrated	O
in	O
one	O
of	O
two	O
studies	O
conducted	O
to	O
date	O
.	O
5,6	O
For	O
patients	O
who	O
have	O
experienced	O
progression	O
after	O
platinum	O
-	O
based	O
therapy	O
and	O
anti	O
-	O
PD-1	O
/	O
L1	O
therapy	O
,	O
treatment	O
options	O
are	O
limited	O
to	O
chemotherapies	O
that	O
have	O
modest	O
activity	O
.	O
7	O
Thus	O
,	O
there	O
is	O
an	O
urgent	O
need	O
for	O
effective	O
and	O
tolerable	O
therapies	O
in	O
patients	O
with	O
locally	O
advanced	O
and	O
metastatic	O
urothelial	O
carcinoma	O
after	O
treatment	O
with	O
platinum	O
and	O
anti	O
-	O
PD-1	O
/	O
L1	O
therapies	O
.	O

Enfortumab	O
vedotin	O
is	O
an	O
investigational	O
antibodydrug	O
conjugate	O
that	O
is	O
comprised	O
of	O
a	O
fully	O
human	O
monoclonal	O
antibody	O
conjugated	O
to	O
the	O
clinically	O
validated	O
microtubule	O
-	O
disrupting	O
agent	O
,	O
monomethyl	O
auristatin	O
E	O
(	O
MMAE	O
)	O
,	O
via	O
a	O
protease	O
-	O
cleavable	O
linker	O
.	O
8,9	O
Enfortumab	O
vedotin	O
targets	O
Nectin-4	O
,	O
a	O
transmembrane	O
protein	O
that	O
belongs	O
to	O
the	O
Nectin	O
family	O
of	O
cell	O
adhesion	O
molecules	O
involved	O
in	O
cellular	O
processes	O
associated	O
with	O
oncogenesis	O
.	O
8,[10][11][12	O
]	O
Nectin-4	O
is	O
highly	O
expressed	O
in	O
several	O
solid	O
tumors	O
,	O
including	O
urothelial	O
,	O
breast	O
,	O
gastric	O
,	O
and	O
lung	O
carcinomas	O
.	O
Expression	O
is	O
weak	O
to	O
moderate	O
in	O
normal	O
skin	O
.	O
8,[13][14][15][16	O
]	O
Enfortumab	O
vedotin	O
binds	O
to	O
cells	O
that	O
express	O
Nectin-4	O
with	O
high	O
affinity	O
,	O
triggering	O
the	O
internalization	O
and	O
release	O
of	O
MMAE	O
in	O
target	O
cells	O
.	O
MMAE	O
disrupts	O
microtubule	O
networks	O
,	O
leading	O
to	O
cell	O
-	O
cycle	O
arrest	O
and	O
apoptotic	O
death	O
of	O
Nectin-4-expressing	O
cells	O
.	O

The	O
phase	O
I	O
dose	O
escalation	O
and	O
expansion	O
study	O
EV-101	O
(	O
ClinicalTrials.gov	O
identifier	O
:	O
NCT02091999	O
)	O
demonstrated	O
that	O
enfortumab	O
vedotin	O
,	O
administered	O
on	O
days	O
1	O
,	O
8	O
,	O
and	O
15	O
of	O
every	O
28-day	O
cycle	O
,	O
has	O
antitumor	O
activity	O
in	O
previously	O
treated	O
patients	O
with	O
metastatic	O
urothelial	O
carcinoma	O
,	O
including	O
those	O
who	O
received	O
platinum	O
-	O
based	O
chemotherapy	O
and	O
anti	O
-	O
PD-1	O
/	O
L1	O
therapy	O
.	O
17	O
Pharmacokinetic	O
data	O
from	O
this	O
study	O
demonstrate	O
a	O
half	O
-	O
life	O
of	O
approximately	O
2	O
days	O
,	O
which	O
supports	O
this	O
dosing	O
schedule	O
.	O
18	O
EV-201	O
,	O
a	O
two	B-study_type
-	I-study_type
cohort	I-study_type
,	I-study_type
single	I-study_type
-	I-study_type
arm	I-study_type
,	I-study_type
phase	I-study_type
II	I-study_type
study	I-study_type
,	O
was	O
designed	O
to	O
establish	O
the	O
efficacy	O
and	O
safety	O
of	O
enfortumab	B-arm_description
vedotin	I-arm_description
in	O
patients	O
with	O
locally	O
advanced	O
or	O
metastatic	O
urothelial	O
carcinoma	O
who	O
were	O
previously	O
treated	O
with	O
anti	O
-	O
PD-1	O
/	O
L1	O
therapy	O
.	O
Cohort	O
1	O
enrolled	O
patients	O
who	O
were	O
previously	O
treated	O
with	O
both	O
platinum	O
chemotherapy	O
and	O
an	O
anti	O
-	O
PD-1	O
/	O
L1	O
therapy	O
,	O
whereas	O
Cohort	O
2	O
continues	O
to	O
enroll	O
patients	O
who	O
were	O
previously	O
treated	O
only	O
with	O
an	O
anti	O
-	O
PD-1	O
/	O
L1	O
therapy	O
.	O
Here	O
,	O
we	O
report	O
results	O
from	O
EV-201	O
Cohort	O
1	O
.	O

Patients	O
with	O
locally	O
advanced	O
or	O
metastatic	O
urothelial	O
carcinoma	O
who	O
were	O
previously	O
treated	O
with	O
anti	O
-	O
PD-1/	O
L1	O
therapy	O
and	O
age	O
18	O
years	O
or	O
older	O
were	O
eligible	O
to	O
enroll	O
if	O
they	O
experienced	O
progression	O
during	O
or	O
after	O
their	O
most	O
recent	O
therapy	O
,	O
had	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
score	O
of	O
1	O
or	O
less	O
,	O
and	O
had	O
adequate	O
baseline	O
organ	O
function	O
.	O
Patients	O
with	O
ongoing	O
sensory	O
or	O
motor	O
neuropathy	O
grade	O
2	O
or	O
greater	O
,	O
active	O
CNS	O
metastases	O
,	O
or	O
uncontrolled	O
diabetes	O
were	O
excluded	O
.	O
Uncontrolled	O
diabetes	O
was	O
defined	O
as	O
hemoglobin	O
A1C	O
of	O
8	O
%	O
or	O
greater	O
or	O
hemoglobin	O
A1C	O
of	O
7	O
%	O
to	O
less	O
than	O
8	O
%	O
with	O
associated	O
diabetes	O
symptomspolyuria	O
or	O
polydipsia	O
-	O
that	O
were	O
not	O
otherwise	O
explained	O
.	O
There	O
were	O
no	O
limits	O
for	O
prior	O
lines	O
of	O
therapy	O
,	O
including	O
taxanes	O
.	O
Full	O
eligibility	O
criteria	O
are	O
available	O
in	O
the	O
protocol	O
(	O
Data	O
Supplement	O
)	O
.	O
patients	O
were	O
discontinued	O
from	O
the	O
study	O
before	O
receiving	O
study	O
treatment	O
;	O
1	O
due	O
to	O
clinical	O
deterioration	O
,	O
1	O
per	O
patient	O
decision	O
,	O
and	O
1	O
due	O
to	O
low	O
hemoglobin	O
levels	O
after	O
screening	O
and	O
enrollment	O
.	O
This	O
latter	O
patient	O
met	O
all	O
eligibility	O
criteria	O
,	O
including	O
adequate	O
hemoglobin	O
level	O
and	O
was	O
enrolled	O
in	O
the	O
study	O
;	O
however	O
,	O
the	O
patient	O
's	O
hemoglobin	O
levels	O
were	O
subsequently	O
found	O
to	O
be	O
low	O
and	O
the	O
investigator	O
withdrew	O
the	O
patient	O
from	O
the	O
study	O
as	O
a	O
result	O
.	O

EV-201	O
is	O
a	O
global	B-study_type
,	I-study_type
single	I-study_type
-	I-study_type
arm	I-study_type
,	I-study_type
two	I-study_type
-	I-study_type
cohort	I-study_type
,	I-study_type
phase	I-study_type
II	I-study_type
multicenter	I-study_type
study	I-study_type
that	O
was	O
designed	O
to	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
enfortumab	B-arm_description
vedotin	I-arm_description
(	O
Fig	O
1	O
)	O
.	O
Cohort	O
1	O
enrolled	O
platinum	O
-	O
and	O
anti	O
-	O
PD-1	O
/	O
L1-treated	O
patients	O
with	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
scores	O
of	O
1	O
or	O
less	O
.	O
Platinum	O
treatment	O
was	O
defined	O
as	O
platinum	O
-	O
containing	O
chemotherapy	O
in	O
the	O
neoadjuvant	O
and/or	O
adjuvant	O
setting	O
with	O
recurrent	O
or	O
progressive	O
disease	O
within	O
12	O
months	O
of	O
completion	O
,	O
or	O
platinum	O
in	O
the	O
locally	O
advanced	O
or	O
metastatic	O
setting	O
.	O

Patients	O
received	O
enfortumab	B-arm_description
vedotin	I-arm_description
1.25	B-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
kg	I-arm_dosage
intravenously	O
over	B-arm_dosage
approximately	I-arm_dosage
30	I-arm_dosage
minutes	I-arm_dosage
on	I-arm_dosage
days	I-arm_dosage
1	I-arm_dosage
,	I-arm_dosage
8	I-arm_dosage
,	I-arm_dosage
and	I-arm_dosage
15	I-arm_dosage
of	I-arm_dosage
each	I-arm_dosage
28-day	I-arm_dosage
cycle	I-arm_dosage
.	O
Weight	O
-	O
based	O
dosing	O
was	O
calculated	O
using	O
the	O
patient	O
's	O
actual	O
body	O
weight	O
,	O
with	O
a	O
maximum	B-arm_dosage
dose	I-arm_dosage
of	I-arm_dosage
125	I-arm_dosage
mg	I-arm_dosage
.	O
Dose	O
modifications	O
were	O
permitted	O
to	O
manage	O
treatment	O
-	O
related	O
hematologic	O
and	O
nonhematologic	O
toxicities	O
and	O
are	O
outlined	O
in	O
the	O
protocol	O
(	O
Data	O
Supplement	O
)	O
.	O
Treatment	O
continued	O
until	O
disease	O
progression	O
,	O
unacceptable	O
toxicity	O
,	O
consent	O
withdrawal	O
,	O
or	O
investigator	O
decision	O
.	O
Additional	O
details	O
are	O
provided	O
in	O
the	O
protocol	O
.	O

Efficacy	O
of	O
enfortumab	B-arm_description
vedotin	I-arm_description
was	O
assessed	O
by	O
appropriate	O
imaging	O
(	O
computed	O
tomography	O
or	O
magnetic	O
resonance	O
imaging	O
)	O
every	O
8	O
weeks	O
(	O
6	O
1	O
week	O
)	O
,	O
then	O
every	O
12	O
weeks	O
(	O
6	O
1	O
week	O
)	O
after	O
1	O
year	O
.	O
Time	O
points	O
for	O
response	O
assessments	O
were	O
calculated	O
from	O
cycle	O
1	O
,	O
day	O
1	O
.	O
Complete	O
or	O
partial	O
responses	O
,	O
as	O
defined	O
by	O
RECIST	O
version	O
1.1	O
,	O
19	O
were	O
confirmed	O
with	O
repeat	O
scans	O
4	O
to	O
5	O
weeks	O
after	O
initial	O
response	O
and	O
assessed	O
by	O
blinded	O
independent	O
central	O
review	O
(	O
BICR	O
)	O
and	O
investigator	O
.	O

Safety	O
assessments	O
included	O
physical	O
and	O
eye	O
examinations	O
,	O
routine	O
chemistry	O
,	O
and	O
hematologic	O
laboratory	O
tests	O
.	O
Adverse	O
events	O
were	O
graded	O
according	O
to	O
the	O
National	O
Cancer	O
Institute	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
,	O
version	O
4.03	O
.	O
Per	O
protocol	O
,	O
certain	O
adverse	O
events	O
observed	O
in	O
the	O
EV-201	O
study	O
were	O
prespecified	O
for	O
assessment	O
and	O
analysis	O
as	O
composite	O
terms	O
and	O
were	O
observed	O
until	O
resolved	O
,	O
returned	O
to	O
baseline	O
,	O
or	O
became	O
chronic	O
and	O
adequately	O
characterized	O
.	O
These	O
events	O
are	O
summarized	O
here	O
in	O
composite	O
terms	O
of	O
peripheral	O
neuropathy	O
,	O
rash	O
,	O
infusion	O
-	O
related	O
reactions	O
,	O
and	O
hyperglycemia	O
.	O
Expression	O
levels	O
of	O
Nectin-4	O
and	O
PD	O
-	O
L1	O
were	O
assessed	O
using	O
validated	O
immunohistochemical	O
assays	O
in	O
archival	O
or	O
fresh	O
tumor	O
samples	O
(	O
Data	O
Supplement	O
)	O
.	O

The	O
Primary	O
end	O
point	O
was	O
confirmed	O
objective	O
response	O
rate	O
as	O
assessed	O
by	O
BICR	O
.	O
Data	O
cutoff	O
was	O
to	O
be	O
at	O
least	O
6	O
months	O
after	O
the	O
last	O
patient	O
in	O
Cohort	O
1	O
received	O
his	O
or	O
her	O
first	O
dose	O
.	O
Key	O
secondary	O
end	O
points	O
were	O
duration	O
of	O
response	O
and	O
progression	B-arm_efficacy_metric
-	I-arm_efficacy_metric
free	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
by	O
BICR	O
and	O
investigator	O
;	O
objective	O
response	O
rate	O
by	O
investigator	O
;	O
and	O
overall	O
survival	O
,	O
safety	O
,	O
and	O
tolerability	O
.	O

The	O
EV-201	O
trial	O
was	O
designed	O
by	O
the	O
sponsors	O
,	O
with	O
contributions	O
from	O
a	O
steering	O
committee	O
of	O
study	O
investigators	O
.	O
Study	O
protocol	O
and	O
amendments	O
were	O
approved	O
by	O
site	O
independent	O
review	O
boards	O
or	O
ethics	O
committees	O
and	O
conducted	O
in	O
accordance	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
the	O
Good	O
Clinical	O
Practice	O
Guidelines	O
of	O
the	O
International	O
Committee	O
on	O
Harmonization	O
.	O
Written	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
patients	O
.	O
Safety	O
was	O
monitored	O
by	O
an	O
independent	O
data	O
-	O
monitoring	O
committee	O
and	O
the	O
sponsor	O
.	O

Objective	O
response	O
rate	O
and	O
its	O
two	O
-	O
sided	O
95	O
%	O
CI	O
were	O
calculated	O
using	O
the	O
Clopper	O
-	O
Pearson	O
method	O
.	O
For	O
timeto	O
-	O
event	O
end	O
points	O
,	O
median	O
survival	O
time	O
was	O
estimated	O
using	O
the	O
Kaplan	O
-	O
Meier	O
method	O
and	O
the	O
associated	O
95	O
%	O
CI	O
was	O
calculated	O
using	O
the	O
complementary	O
log	O
-	O
log	O
transformation	O
.	O

With	O
100	O
patients	O
in	O
Cohort	O
1	O
,	O
there	O
is	O
a	O
98	O
%	O
chance	O
of	O
observing	O
ORR	O
with	O
lower	O
-	O
limit	O
of	O
the	O
exact	O
95	O
%	O
CI	O
excluding	O
a	O
historical	O
response	O
rate	O
of	O
10	O
%	O
,	O
20	O
if	O
the	O
true	O
ORR	O
is	O
25	O
%	O
.	O
The	O
complete	O
statistical	O
analysis	O
plan	O
is	O
available	O
along	O
with	O
the	O
protocol	O
in	O
the	O
Data	O
Supplement	O
.	O

There	O
(	O
Fig	O
2A	O
)	O
.	O
Investigator	O
-	O
assessed	O
responses	O
,	O
including	O
objective	O
response	O
rate	O
,	O
duration	O
of	O
response	O
,	O
tumor	O
reduction	O
,	O
and	O
progression	B-arm_efficacy_metric
-	I-arm_efficacy_metric
free	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
,	O
were	O
similar	O
to	O
those	O
assessed	O
by	O
BICR	O
(	O
Data	O
Supplement	O
;	O
Appendix	O
Table	O
A2	O
,	O
online	O
only	O
;	O
and	O
Appendix	O
Figs	O
A2	O
,	O
A3	O
,	O
and	O
A4	O
,	O
online	O
only	O
)	O
.	O

Responses	O
across	O
all	O
subgroups	O
analyzed	O
were	O
consistent	O
with	O
overall	O
study	O
results	O
.	O
Objective	O
responses	O
occurred	O
regardless	O
of	O
patients	O
'	O
responses	O
to	O
prior	O
anti	O
-	O
PD-1	O
/	O
L1	O
therapy	O
(	O
56	O
%	O
in	O
responders	O
and	O
41	O
%	O
in	O
nonresponders	O
)	O
.	O
Similar	O
responses	O
were	O
observed	O
in	O
patients	O
with	O
poor	O
prognostic	O
characteristics	O
,	O
including	O
liver	O
metastases	O
(	O
38	O
%	O
)	O
,	O
and	O
three	O
or	O
more	O
prior	O
lines	O
of	O
therapy	O
(	O
41	O
%	O
;	O
Fig	O
3	O
)	O
.	O

Target	O
lesions	O
were	O
reduced	O
in	O
a	O
majority	O
of	O
evaluable	O
patients	O
(	O
84	O
%	O
;	O
Fig	O
2B	O
)	O
.	O
Estimated	O
median	B-arm_efficacy_metric
progression	I-arm_efficacy_metric
-	I-arm_efficacy_metric
free	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
was	O
5.8	B-arm_efficacy_results
months	I-arm_efficacy_results
(	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
,	I-arm_efficacy_results
4.9	I-arm_efficacy_results
to	I-arm_efficacy_results
7.5	I-arm_efficacy_results
months	I-arm_efficacy_results
;	O
Appendix	O
Fig	O

Treatment	O
-	O
related	O
rash	O
-	O
as	O
a	O
composite	O
term	O
-	O
occurred	O
in	O
48	O
%	O
of	O
patients	O
,	O
most	O
of	O
which	O
were	O
low	O
grade	O
(	O
75	O
%	O
grade	O
#	O
2	O
)	O
with	O
onset	O
in	O
the	O
first	O
treatment	O
cycle	O
.	O
Two	O
patients	O
discontinued	O
treatment	O
as	O
a	O
result	O
of	O
rash	O
,	O
one	O
of	O
whom	O
experienced	O
a	O
grade	O
3	O
rash	O
reported	O
as	O
Stevens	O
-	O
Johnson	O
syndrome	O
.	O
Onset	O
of	O
symptoms	O
for	O
this	O
event	O
was	O
4	O
days	O
after	O
the	O
initial	O
dose	O
and	O
the	O
rash	O
resolved	O
after	O
the	O
discontinuation	O
of	O
enfortumab	B-arm_description
vedotin	I-arm_description
and	O
treatment	O
with	O
systemic	O
corticosteroids	O
.	O
Of	O
all	O
patients	O
who	O
experienced	O
rash	O
,	O
73	O
%	O
experienced	O
complete	O
resolution	O
and	O
20	O
%	O
had	O
some	O
improvement	O
at	O
last	O
follow	O
-	O
up	O
.	O
Most	O
patients	O
(	O
75	O
%	O
)	O
with	O
ongoing	O
rash	O
had	O
grade	O
1	O
at	O
last	O
follow	O
-	O
up	O
.	O
Three	O
patients	O
had	O
infusion	O
site	O
extravasation	O
,	O
of	O
which	O
two	O
cases	O
were	O
considered	O
serious	O
.	O
All	O
patients	O
with	O
extravasation	O
recovered	O
completely	O
and	O
were	O
able	O
to	O
continue	O
treatment	O
.	O

Treatment	O
-	O
related	O
hyperglycemia	O
occurred	O
in	O
few	O
patients	O
(	O
11	O
%	O
)	O
,	O
regardless	O
of	O
known	O
hyperglycemia	O
at	O
baseline	O
.	O
Nineteen	O
patients	O
had	O
hyperglycemia	O
at	O
baseline	O
and	O
,	O
of	O
these	O
,	O
68	O
%	O
did	O
not	O
develop	O
treatment	O
-	O
related	O
events	O
.	O
Of	O
patients	O
without	O
hyperglycemia	O
at	O
baseline	O
,	O
8	O
%	O
developed	O
treatment	O
-	O
related	O
hyperglycemia	O
.	O
Hyperglycemia	O
in	O
seven	O
of	O
14	O
patients	O
with	O
these	O
events	O
was	O
grade	O
2	O
or	O
less	O
.	O
The	O
single	O
patient	O
with	O
grade	O
4	O
hyperglycemia	O
did	O
not	O
have	O
known	O
baseline	O
hyperglycemia	O
and	O
,	O
per	O
protocol	O
,	O
treatment	O
was	O
discontinued	O
.	O
The	O
patient	O
later	O
recovered	O
and	O
had	O
no	O
ongoing	O
need	O
for	O
insulin	O
or	O
oral	O
hypoglycemic	O
agents	O
.	O
This	O
was	O
the	O
only	O
discontinuation	O
as	O
a	O
result	O
of	O
hyperglycemia	O
.	O
Among	O
patients	O
who	O
experienced	O
hyperglycemia	O
,	O
57	O
%	O
achieved	O
complete	O
resolution	O
and	O
14	O
%	O
experienced	O
some	O
improvement	O
.	O

There	O
were	O
no	O
treatment	O
-	O
related	O
deaths	O
during	O
the	O
30-day	O
safety	O
reporting	O
period	O
.	O
One	O
death	O
as	O
a	O
result	O
of	O
interstitial	O
lung	O
disease	O
that	O
occurred	O
outside	O
the	O
safety	O
reporting	O
period	O
was	O
reported	O
as	O
treatment	O
related	O
.	O
This	O
death	O
was	O
confounded	O
by	O
prolonged	O
high	O
-	O
dose	O
corticosteroid	O
use	O
and	O
suspected	O
Pneumocystis	O
jiroveci	O
pneumonia	O
.	O

Patient	O
populations	O
for	O
analysis	O
.	O
The	O
full	O
analysis	O
set	O
(	O
FAS	O
)	O
included	O
all	O
patients	O
who	O
were	O
enrolled	O
in	O
the	O
study	O
who	O
received	O
any	O
amount	O
of	O
enfortumab	B-arm_description
vedotin	I-arm_description
.	O
The	O
FAS	O
was	O
used	O
as	O
the	O
primary	O
analysis	O
set	O
for	O
efficacy	O
end	O
points	O
.	O
The	O
safety	O
analysis	O
set	O
included	O
all	O
patients	O
who	O
received	O
any	O
amount	O
of	O
enfortumab	B-arm_description
vedotin	I-arm_description
and	O
was	O
therefore	O
used	O
for	O
all	O
safety	O
analyses	O
.	O

Biomarker	O
assessments	O
.	O
Samples	O
for	O
exploratory	O
biomarkers	O
were	O
collected	O
at	O
protocol	O
-	O
specified	O
timepoints	O
defined	O
in	O
the	O
schedule	O
of	O
events	O
.	O
Biomarker	O
assessments	O
were	O
not	O
used	O
for	O
patient	O
selection	O
.	O
Programmed	O
death	O
ligand	O
1	O
levels	O
were	O
assessed	O
in	O
tumor	O
-	O
infiltrating	O
immune	O
cells	O
using	O
DAKO	O
22C3	O
immunohistochemistry	O
to	O
determine	O
PD	O
-	O
L1	O
combined	O
positive	O
score	O
of	O
less	O
than	O
10	O
versus	O
10	O
or	O
greater	O
in	O
archival	O
or	O
fresh	O
tumor	O
samples	O
.	O
Overall	O
,	O
78	O
(	O
65	O
%	O
)	O
of	O
120	O
evaluable	O
patients	O
had	O
a	O
programmed	O
death	O
ligand	O
1	O
combined	O
positive	O
score	O
of	O
less	O
than	O
10	O
.	O
2	O
3	O
4	O
5	O
6	O
7	O
8	O
11	O
12	O
13	O
14	O
15	O
16	O
17	O
18	O
9Time	O
(	O
months	O
)	O
Progression	B-arm_efficacy_metric
-	I-arm_efficacy_metric
Free	I-arm_efficacy_metric
Survival	I-arm_efficacy_metric
(	O
%	O
)	O
†Improvement	O
defined	O
as	O
at	O
least	O
one	O
grade	O
improvement	O
from	O
the	O
worst	O
grade	O
at	O
the	O
last	O
assessment	O
.	O
‡Resolution	O
defined	O
as	O
a	O
return	O
to	O
baseline	O
grade	O
or	O
better	O
at	O
the	O
last	O
assessment	O
.	O